A BOLD approach that's well tolerated
A well-established safety profile1
- BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp1
- The most common adverse events reported were GI side effects, with the majority being mild and transient6-8
- 2 out of 545 patients studied in phase 3 clinical trials discontinued treatment with BREXAFEMME due to dizziness (1 patient) and vomiting (1 patient)1
MOST COMMON ADVERSE REACTIONS (INCIDENCE ≥2%)1
| BREXAFEMME (N=545) |
PLACEBO (N=275) |
|
|---|---|---|
| Diarrhea | 16.7% | 3.3% |
| Nausea | 11.9% | 4.0% |
| Abdominal Pain* | 11.4% | 5.1% |
| Dizziness† | 3.3% | 2.5% |
| Vomiting | 2.0% | 0.7% |
| BREXAFEMME (N=545) |
|---|
| Diarrhea 16.7% |
| Nausea 11.9% |
| Abdominal Pain* 11.4% |
| Dizziness† 3.3% |
| Vomiting 2.2% |
| PLACEBO (N=275) |
|---|
| Diarrhea 3.3% |
| Nausea 4.0% |
| Abdominal Pain* 5.1% |
| Dizziness† 2.5% |
| Vomiting 0.7% |
Prescribe with confidence
- There was no QTc interval prolongation at >5 times the concentration of the indicated dose in clinical trials1
- There is a pregnancy safety study for BREXAFEMME. If BREXAFEMME is inadvertently administered during pregnancy or if pregnancy is detected within 4 days after a patient receives BREXAFEMME, pregnant women exposed to BREXAFEMME and healthcare providers should report pregnancies to SCYNEXIS, Inc. at 1-888-982-SCYX (7299)
